Cat. No.: HY-144998

NVP-DKY709

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

NVP-DKY709 is an orally active and selective IKZF2 molecular glue degrader with the D_max and DC₅₀ of 53% and 4 nM, respectively. In addition, NVP-DKY709 can degrade IKZF4 (DC₅₀: 13 nM) and SALL4 (DC₅₀: 2 nM). NVP-DKY709 exerts anti-tumor activity by binding with CRBN to change conformation and recruit and degrade IKZF2.

For research use only. We do not sell to patients.

Purity: 99.66%
CAS No.: 2291360-73-9
Formula: C₂₅H₂₇N₃O₃
Molecular Weight:417.50

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

NVP-DKY709 Chemical Structure

CAS No.: 2291360-73-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

IZKF2

4 nM (DC₅₀)

IKZF4

13 nM (DC₅₀)

All IKZF Family Isoforms :

In Vitro

NVP-DKY709 (2.5μM; 16 h) only significantly down-regulates IKZF2 levels, but does not affect IKZF1, IKZF3 and IKZF5 levels in Jurkat cells^[1].
NVP-DKY709 (0.001-1 μM; 24 h) increases IL-2 concentration in a dose-dependent manner in Phytohemagglutinin (HY-N7038) treated Jurkat cells^[1].
NVP-DKY709 (2.5nM-2.4μM; 10 days) decreases IKZF2⁺ cells and increases IFN-γ expression in T cells with impaired function^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

NVP-DKY709 (100 mg/kg; oral administration; 28 days) has antitumor effect in mouse model of breast cancer^[1].
Pharmacokinetic Analysis in cynomolgus monkeys and mouse^[1]

Parameter average value	CL (mL/min•kg)	V_ss (L/kg)	t_{1/2term. iv} (h)	AUC (ng/mL*h) p.o.	C_max (ng/mL) p.o.	t_max (h) p.o.	Oral BA (%)
Mouse (2 mg/kg iv \| 3 mg/kg po)	18	1.9	2.8	1506	482	1	53
Cynomolgus monkeys (0.3 mg/kg iv \| 1.0 mg/kg po)	26	8.6	5.7	516	41	4	89

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

MDA-MB-231 treated mice with a humanized (hematopoietic stem cell derived) immune system^[1]
Dosage:

100 mg/kg
Administration:

Oral administration (p.o.); 28 days
Result:

Resulted in robust IKZF2 degradation in both tumor and peripheral blood Treg cells.
Reduced tumor growth.
Reduced expression of key biomarkers of fitness, FOXP3 and CD25 in the tumor-infiltrating Treg cells.

Chemical Information

CAS No. 2291360-73-9
Appearance Solid
Molecular Weight 417.50
Formula C₂₅H₂₇N₃O₃
Color White to light yellow
SMILES

O=C1CCC(C(N1)=O)N2CC3=CC(C4CCN(CC4)CC5=CC=CC=C5)=CC=C3C2=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Pharmaceutics

CC-90009, a Cereblon E3 Ligase Modulator, Exhibits Antiviral Efficacy Against JEV In Vitro and In Vivo via Targeted Degradation of GSPT1 and Viral NS5 Protein. [Abstract]

2025 Nov 27;17(12):1524. PMID: 41471039

Solvent & Solubility

In Vitro:

DMSO : 16.67 mg/mL (39.93 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3952 mL

11.9760 mL

23.9521 mL

5 mM

0.4790 mL

2.3952 mL

4.7904 mL

10 mM

0.2395 mL

1.1976 mL

2.3952 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (2.40 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (2.40 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1 mg/mL (2.40 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 15.15 mg/mL (36.29 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Bonazzi S, et al. Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy. Cell Chem Biol. 2023 Mar 16;30(3):235-247.e12. [Content Brief]

[2]. Simone BONAZZI, et al. Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives. WO2020128972 A1.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3952 mL	11.9760 mL	23.9521 mL	59.8802 mL
	5 mM	0.4790 mL	2.3952 mL	4.7904 mL	11.9760 mL
	10 mM	0.2395 mL	1.1976 mL	2.3952 mL	5.9880 mL
	15 mM	0.1597 mL	0.7984 mL	1.5968 mL	3.9920 mL
	20 mM	0.1198 mL	0.5988 mL	1.1976 mL	2.9940 mL
	25 mM	0.0958 mL	0.4790 mL	0.9581 mL	2.3952 mL
	30 mM	0.0798 mL	0.3992 mL	0.7984 mL	1.9960 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

NVP-DKY709

MCE Bioactive Compound Library

Molecular Glue-like Compound Library

Publications Citing Use of MedChemExpress (MCE) NVP-DKY709

All IKZF Family Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

NVP-DKY709

MCE Bioactive Compound Library

Molecular Glue-like Compound Library

Publications Citing Use of MedChemExpress (MCE) NVP-DKY709

All IKZF Family Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

NVP-DKY709 Related Classifications

HY-144998 Related Classifications